List of Excipients in Branded Drug LAMPIT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc	LAMPIT	nifurtimox	50419-750	DIBASIC CALCIUM PHOSPHATE DIHYDRATE	2027-08-06
Bayer HealthCare Pharmaceuticals Inc	LAMPIT	nifurtimox	50419-750	MAGNESIUM STEARATE	2027-08-06
Bayer HealthCare Pharmaceuticals Inc	LAMPIT	nifurtimox	50419-750	SILICON DIOXIDE	2027-08-06
Bayer HealthCare Pharmaceuticals Inc	LAMPIT	nifurtimox	50419-750	SODIUM LAURYL SULFATE	2027-08-06
Bayer HealthCare Pharmaceuticals Inc	LAMPIT	nifurtimox	50419-750	STARCH, CORN	2027-08-06

LAMPIT Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

LAMPIT (nifurtimox) is a differentiated Chagas disease product whose commercial value depends on pediatric usability, global supply reliability, and formulation access rather than active-ingredient exclusivity. The core opportunity is to improve taste, dispersibility, dose flexibility, and regional manufacturability while preserving the product’s FDA-approved performance and orphan-drug positioning.

What is LAMPIT and how is it regulated?

LAMPIT contains nifurtimox, an antitrypanosomal drug used to treat Chagas disease caused by Trypanosoma cruzi. The U.S. Food and Drug Administration approved LAMPIT on Aug. 7, 2020, under New Drug Application 214927 for adult and pediatric patients weighing at least 2.5 kg. The approved product is available as 30 mg and 120 mg tablets.[1]

The label permits tablets to be swallowed whole or dispersed in water. This administration option is commercially important because Chagas disease treatment includes young children and patients who have difficulty swallowing conventional tablets.

Attribute	LAMPIT status
Active ingredient	Nifurtimox
Therapeutic area	Chagas disease
FDA applicant and marketer	Bayer HealthCare Pharmaceuticals Inc.
FDA approval	Aug. 7, 2020
NDA	214927
Dosage forms	30 mg and 120 mg tablets
Pediatric use	Patients weighing at least 2.5 kg
Administration	Whole tablet or dispersion in water
FDA designation	Orphan drug
U.S. orphan exclusivity	Expected to extend through Aug. 7, 2027, absent loss or earlier termination
Biosimilar pathway	Not applicable; LAMPIT is a small-molecule drug

The FDA approval was supported by orphan-drug incentives and a limited-patient population. Because nifurtimox is an established active ingredient, formulation execution and regulatory positioning are more important than composition-of-matter exclusivity.

What excipients are used in LAMPIT tablets?

The LAMPIT prescribing information identifies a conventional solid-dose excipient system designed to support tablet manufacture, mechanical integrity, dispersion, and dose uniformity. The listed inactive ingredients include microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, colloidal silicon dioxide, sodium lauryl sulfate, hypromellose, lactose monohydrate, talc, and titanium dioxide.[1]

Excipient	Likely formulation function	Strategic relevance
Microcrystalline cellulose	Diluent and compression aid	Supports robust tablet manufacture
Lactose monohydrate	Filler and bulking agent	Creates potential lactose-intolerance and supply-chain considerations
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup in water
Povidone	Binder	Improves granule and tablet integrity
Magnesium stearate	Lubricant	Controls ejection and manufacturing friction
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow
Sodium lauryl sulfate	Wetting agent	May improve wetting of nifurtimox particles
Hypromellose	Film-coating polymer	Supports coating integrity and appearance
Talc	Coating aid and anti-tacking agent	Supports coating manufacture
Titanium dioxide	Opacifier and colorant	Provides visual differentiation and light protection

The formulation is not simply a conventional immediate-release tablet. The product must also disperse adequately in water and remain suitable for weight-based pediatric dosing. That requirement places greater importance on wetting, disintegration, particle-size distribution, and dose uniformity than would apply to a standard adult tablet.

What formulation characteristics create commercial opportunities?

The strongest opportunities are in pediatric administration and patient acceptability. Nifurtimox treatment can require multiple daily doses over an extended course, which increases the commercial value of an excipient system that reduces swallowing difficulty and improves dose administration.

Taste masking and palatability

Nifurtimox has an unfavorable taste profile. LAMPIT’s dispersion option can expose the active ingredient to the oral cavity, making taste control commercially relevant. Potential approaches include:

• Polymer-based taste masking
• Ion-exchange or lipid-based drug-resin systems
• pH-modified granules
• Coated microparticles
• Flavor systems compatible with water dispersion
• Sweetener systems with controlled osmolality
• Multiparticulate sachets or reconstitutable granules

Taste masking must not compromise rapid dispersion, nifurtimox release, dose uniformity, or stability. A coated-particle system may provide stronger intellectual-property differentiation than merely changing a flavor or sweetener.

Improved dispersibility

The current tablet is dispersed in water before administration for some patients. A next-generation formulation could improve:

• Dispersion time
• Sedimentation control
• Redispersibility
• Dose recovery from the cup or oral syringe
• Uniformity during administration
• Palatability after dispersion
• Stability over the recommended administration window

A suspending agent could improve dose uniformity, but it may slow release or produce unacceptable viscosity. The most commercially useful formulation would disperse quickly without requiring vigorous shaking or specialized equipment.

Flexible pediatric dosing

Weight-based dosing creates a need for accurate dose delivery across a broad pediatric population. Commercial candidates include:

• Lower-strength tablets
• Mini-tablets
• Scored tablets with improved subdivision performance
• Granules for oral suspension
• Powder-in-bottle systems
• Unit-dose sachets
• Oral dispersible tablets
• Oral liquids with improved chemical and microbial stability

Any alternative must support accurate dosing at the lower end of the approved weight range. A formulation that reduces tablet-count burden for larger children and adults could also improve adherence.

Stability and logistics

Chagas disease treatment is relevant in regions with variable storage conditions and healthcare infrastructure. Excipient selection can support commercial expansion by improving:

• Moisture resistance
• Heat stability
• Photostability
• Packaging compatibility
• Shelf life
• Robustness during transport
• Resistance to repeated container opening

Aluminum-aluminum blisters, high-barrier bottles, desiccant systems, and unit-dose packaging can complement the excipient strategy. Packaging innovations may provide practical differentiation even where formulation patent protection is limited.

What patents protect LAMPIT and its formulation?

LAMPIT’s primary commercial protection comes from regulatory exclusivity and product-specific know-how rather than a clearly dominant active-ingredient patent estate. Nifurtimox was discovered decades before the U.S. approval, so composition-of-matter protection is not commercially available.

The relevant protection categories are:

Protection category	LAMPIT relevance
Nifurtimox composition patent	Expired or unavailable because of the age of the active ingredient
Formulation patents	May cover tablet composition, dispersibility, taste masking, particle engineering, or manufacturing
Method-of-use patents	Could cover treatment of defined Chagas populations or dosing regimens, subject to validity and listing
Orphan-drug exclusivity	FDA exclusivity for the approved use, expected through August 2027
Trade secrets	Manufacturing process, granulation parameters, coating conditions, analytical methods, and supplier controls
Regulatory data	NDA clinical and CMC package, with protection determined by U.S. regulatory rules

No biosimilar analysis applies because nifurtimox is a small molecule. A generic applicant would generally pursue an Abbreviated New Drug Application rather than a biosimilar application.

The commercial importance of any formulation patent depends on whether it covers a necessary product attribute. A narrow patent on a particular flavor or excipient percentage may have limited blocking value. A broader claim covering a dispersible nifurtimox dosage form, pediatric dosing system, or taste-masked multiparticulate platform could create stronger protection.

When does LAMPIT lose U.S. exclusivity?

LAMPIT’s seven-year orphan-drug exclusivity is expected to expire in August 2027, based on the Aug. 7, 2020 approval date.[1] Orphan exclusivity blocks FDA approval of the same drug for the same disease or condition during the exclusivity period, subject to statutory exceptions.

Orphan exclusivity is separate from patent protection. It does not prevent all forms of competition, and it does not create permanent protection for nifurtimox. After the exclusivity period ends, an ANDA applicant could seek approval if it can establish pharmaceutical equivalence, bioequivalence, and compliance with applicable FDA requirements.

FDA exclusivity does not automatically establish that no generic can prepare or file an application before the expiration date. Patent and regulatory strategies therefore need to be analyzed separately.

What generic entry risks exist for LAMPIT?

Generic entry risk is likely to increase after orphan exclusivity expires, but product complexity may reduce the speed of substitution.

Conventional tablet risk

A generic manufacturer may find the 30 mg and 120 mg tablet strengths relatively accessible if the reference product has conventional immediate-release characteristics and straightforward bioequivalence requirements. The main barriers would be:

• Access to qualified nifurtimox API
• Analytical method development
• Demonstration of content uniformity
• Matching dissolution and dispersion behavior
• Pediatric administration requirements
• Manufacturing economics for a small market

Dispersion-related risk

Because LAMPIT can be dispersed in water, the reference product’s administration instructions may create additional development requirements. A generic product may need to show that its tablet behaves equivalently when administered through the same route and in the same manner.

A formulation with distinctive taste masking, particle engineering, or suspension behavior could increase the cost of generic development. Those attributes are more difficult to replicate than tablet hardness and dissolution alone.

Market-size risk

Chagas disease is a significant public-health problem, but the addressable U.S. commercial market is limited. This reduces the incentive for multiple generic entrants unless demand is supported by public procurement, international programs, or expanded geographic registrations.

How strong is the LAMPIT patent and formulation estate?

The estate should be viewed as moderate for commercial formulation protection and weaker for fundamental molecule protection.

Strengths

• Orphan-drug exclusivity protects the approved U.S. indication through approximately August 2027.
• Pediatric dispersibility creates technical requirements beyond a standard swallowable tablet.
• Manufacturing process parameters may be difficult to reproduce without development work.
• Taste-masking and low-dose weight-based administration create opportunities for platform patents.
• Trade secrets may protect critical process and analytical details even where patent claims are narrow.

Weaknesses

• Nifurtimox is an old active ingredient.
• Composition-of-matter exclusivity is unavailable.
• Generic applicants may be able to develop alternative excipient systems.
• A conventional tablet formulation may not create a strong barrier after regulatory exclusivity expires.
• The U.S. market may not support extensive patent litigation.

The strongest defensive strategy would combine a broad formulation patent with narrower continuation claims covering particle size, coating composition, dispersion performance, taste masking, and pediatric dose delivery.

What excipient products could compete with LAMPIT?

Potential competing products would not necessarily use the same excipients. A competitor could pursue a different dosage-form architecture.

Product concept	Primary commercial advantage	Main development risk
Taste-masked dispersible tablet	Better pediatric acceptance	Taste masking may delay release
Oral granules	Flexible weight-based dosing	Stability and dose recovery
Reconstitutable suspension	Easy administration for young children	Microbial control and sedimentation
Mini-tablets	Accurate dose flexibility	Manufacturing and swallowing performance
Orodispersible tablet	No water required	Taste exposure and moisture sensitivity
Nifurtimox sachets	Low-cost distribution	Packaging and content uniformity
Multiparticulate capsule	Dose flexibility and taste masking	Higher manufacturing complexity
Coated tablet	Improved stability and identification	May not solve pediatric administration

A formulation company could license technology to Bayer or pursue a post-exclusivity generic strategy. The most attractive licensing package would include validated taste masking, low-cost pediatric dosing, and a manufacturing process compatible with high-throughput production.

Which companies could challenge or partner around LAMPIT?

Bayer is the principal commercial stakeholder for LAMPIT. Potential counterparties include:

• Generic pharmaceutical manufacturers with neglected-disease portfolios
• Contract development and manufacturing organizations
• Pediatric formulation specialists
• Taste-masking technology companies
• Regional manufacturers in Latin America
• Public-health procurement organizations
• Universities and nonprofit drug-development groups

The most realistic near-term commercial pathway is technology licensing or contract development rather than a large branded competitive launch. A formulation partner could offer Bayer a lifecycle-management product or support supply expansion in countries where Chagas disease is endemic.

No major LAMPIT-specific Paragraph IV litigation or settlement should be assumed without a current review of FDA Orange Book records, federal court dockets, and ANDA patent certifications. The absence of publicly established litigation does not eliminate future challenge risk, particularly as the orphan-exclusivity expiration approaches.

What is the commercial opportunity for improved LAMPIT excipients?

The opportunity is concentrated in four areas.

Pediatric adherence

Taste masking and easy dispersion may reduce treatment refusal and administration errors. This is the highest-value formulation objective because the approved population includes very young children.

Regional access

A stable, low-cost dosage form could support distribution in Latin America and other regions with Chagas disease burden. Formulations that avoid refrigeration, reduce packaging volume, and tolerate heat and humidity have procurement value.

Lifecycle management

A new formulation could extend commercial relevance after U.S. orphan exclusivity expires if it offers clinically meaningful advantages. Regulatory exclusivity for a new formulation would depend on the specific FDA pathway and supporting data.

Manufacturing economics

Excipient substitution can reduce dependence on specialized suppliers, improve batch yields, and reduce tablet defects. However, any change must preserve critical quality attributes and may require regulatory notification or approval.

What FDA requirements apply to a new LAMPIT formulation?

A new LAMPIT formulation would likely require assessment under an NDA supplement, a new NDA, or an ANDA, depending on the sponsor’s relationship to the reference product and the extent of the change.

Key regulatory considerations include:

• Pharmaceutical equivalence
• Bioequivalence or comparative performance
• Dissolution and dispersion testing
• Content uniformity
• Stability under ICH conditions
• Extractables and leachables
• Microbial limits for liquid or reconstituted products
• Pediatric acceptability
• Dose delivery through oral syringes or cups
• Compatibility with administration vehicles
• Manufacturing-process validation
• Excipient safety for pediatric patients

A new excipient or a novel use level may require additional toxicology or regulatory justification. The most efficient development path generally uses established compendial excipients with a well-supported pediatric safety profile.

Key Takeaways

• LAMPIT is nifurtimox, a pediatric-focused Chagas disease tablet approved by FDA in 2020.
• Its commercial differentiation depends on dispersion, dose flexibility, and pediatric usability.
• The listed excipients support immediate-release tablet manufacture, wetting, disintegration, binding, lubrication, and coating.
• Taste masking is the clearest formulation opportunity.
• Orphan-drug exclusivity is expected to expire in August 2027.
• Nifurtimox’s age limits composition-of-matter protection, increasing the value of formulation patents and manufacturing trade secrets.
• No biosimilar pathway applies.
• Generic entry risk is likely to rise after orphan exclusivity, but pediatric dispersion and market size may limit the number of entrants.
• The strongest commercial products would combine taste masking, accurate weight-based dosing, heat stability, low packaging cost, and simple administration.
• Licensing opportunities are most plausible for pediatric formulation technology, regional manufacturing, and supply-chain optimization.

FAQs

Can a new excipient create a separate LAMPIT patent?

Yes. A new formulation may support patent claims covering the excipient combination, concentration ranges, particle coating, taste-masking system, dispersion properties, or manufacturing process. Patent strength depends on novelty, non-obviousness, written description, and claim breadth.

Does LAMPIT require a pediatric liquid formulation?

No. The FDA-approved product is a tablet that can be dispersed in water. A liquid, granule, or mini-tablet formulation could still create commercial value by improving administration and dose flexibility.

Is nifurtimox suitable for an ANDA after 2027?

Potentially. An applicant would need to satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, quality, labeling, and any applicable patent certifications. The exact pathway would depend on the Orange Book listing and the reference product’s regulatory status at the time of filing.

Which excipient issue is most likely to affect LAMPIT adherence?

Taste is likely the leading issue when tablets are dispersed in water. A formulation that improves taste without slowing release or reducing dose uniformity would have the clearest adherence rationale.

Could a LAMPIT formulation be commercialized outside the United States?

Yes. Regional commercialization could target Latin America and other countries with Chagas disease prevalence. Each market would require separate regulatory, procurement, labeling, manufacturing, and intellectual-property analysis.

References

1. U.S. Food and Drug Administration. (2020). LAMPIT (nifurtimox) tablets, prescribing information. Bayer HealthCare Pharmaceuticals Inc. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
3. U.S. Food and Drug Administration. (2024). Orphan drug designations and approvals. https://www.accessdata.fda.gov/scripts/opdq/orphadirs/
4. World Health Organization. (2023). Chagas disease. https://www.who.int/news-room/fact-sheets/detail/chagas-disease
5. U.S. Food and Drug Administration. (2019). Guidance for industry: Size of beads in drug products labeled for sprinkle. https://www.fda.gov/regulatory-information/search-fda-guidance-documents